Understanding Akero Therapeutics Inc (AKRO) through its ratios

In the latest session, Akero Therapeutics Inc (NASDAQ: AKRO) closed at $25.26 up 3.31% from its previous closing price of $24.45. In other words, the price has increased by $+0.81 from its previous closing price. On the day, 851489 shares were traded. AKRO stock price reached its highest trading level at $25.43 during the session, while it also had its lowest trading level at $23.74.

Ratios:

For a deeper understanding of Akero Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 29.27 and its Current Ratio is at 29.27. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on September 19, 2023, initiated with a Overweight rating and assigned the stock a target price of $69.

On August 28, 2023, UBS started tracking the stock assigning a Buy rating and target price of $83.

Morgan Stanley Upgraded its Equal-Weight to Overweight on January 27, 2023, whereas the target price for the stock was revised from $40 to $65.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 13 ’24 when Cheng Andrew sold 1,969 shares for $28.33 per share. The transaction valued at 55,782 led to the insider holds 589,447 shares of the business.

White William Richard sold 724 shares of AKRO for $20,511 on Mar 13 ’24. The Chief Financial Officer now owns 49,630 shares after completing the transaction at $28.33 per share. On Mar 13 ’24, another insider, Yale Catriona, who serves as the Chief Development Officer of the company, sold 723 shares for $28.33 each. As a result, the insider received 20,483 and left with 77,692 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 1.74B and an Enterprise Value of 1.22B.

Stock Price History:

Over the past 52 weeks, AKRO has reached a high of $58.38, while it has fallen to a 52-week low of $11.25. The 50-Day Moving Average of the stock is 24.29, while the 200-Day Moving Average is calculated to be 31.51.

Shares Statistics:

For the past three months, AKRO has traded an average of 1.42M shares per day and 1.53M over the past ten days. A total of 68.95M shares are outstanding, with a floating share count of 57.62M. Insiders hold about 16.43% of the company’s shares, while institutions hold 82.85% stake in the company. Shares short for AKRO as of Mar 15, 2024 were 9.47M with a Short Ratio of 6.67, compared to 8.89M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.74% and a Short% of Float of 14.04%.

Earnings Estimates

There are 6 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$1 for the current quarter, with a high estimate of -$0.79 and a low estimate of -$1.15, while EPS last year was -$0.55. The consensus estimate for the next quarter is -$1, with high estimates of -$0.8 and low estimates of -$1.2.

Analysts are recommending an EPS of between -$2.89 and -$5.1 for the fiscal current year, implying an average EPS of -$3.97. EPS for the following year is -$4.33, with 7 analysts recommending between -$3.36 and -$5.4.

Most Popular

[the_ad id="945"]